In this article, Harriet Wall (Commissioning Editor, Future Medicinal Chemistry) discusses some of the highlights seen in the journal over the past 12 months.
One of our most read articles this year, ‘Peeking at G-protein-coupled receptors through the molecular dynamics keyhole’ reviewed the main contributions of molecular dynamics (MD) to the study of G-protein-coupled receptors (GPCRs). Where most systems can be partially explained using static parameters, MD allows for the time dependent description of biological processes – giving rise to a more accurate description of GPCR ligand recognition, activation mechanisms, and biased agonism. Understanding the dynamics of a target is integral to the development of related drugs – making MD a key asset to this field.
Primary research plays an integral role in the development of medicinal chemistry. Many research articles were published in Future Medicinal Chemistry last year – popular titles amongst these included ‘Discovery of arginine-containing tripeptides as a new class of pancreatic lipase inhibitors’, ‘Synthesis and evaluation of novel 7H-pyrrolo-[2,3-d]pyrimidine derivatives as potential anticancer agents’ and ‘A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C’.
In addition to our core content of Reviews, Perspectives and Original Research, the journal also featured content on topical areas of debate relevant to academia and industry; including Editorials, Commentaries, and more. Of interest is ‘Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?’. In this Editorial, Mohamed Benchekroun (Université Paris-Saclay; Paris, France) and Samuele Maramai (University of Sussex; Brighton, UK) discussed alternatives to the mono-target approach for the treatment of neurodegenerative diseases. Multitarget-directed ligands (MTDLs) have the potential to modulate multiple biological processes – once an effective combination of targets has been selected, drug candidates can be developed which provide synergistic therapy for disease.
As with last year, we have seen a huge engagement in the topic of computational chemistry in drug discovery, such as one paper shedding light on a novel area of research – utilizing deep generative neural networks in de novo drug discovery, by Jianfeng Pei et al. From QSAR modelling to big data, computational chemistry has become an essential tool for modern day drug discovery – and the interest we have seen in this field proves its importance for the future of medicinal chemistry.
Exclusive interviews with RxNet
As usual, we continued our partnership with RxNet, providing members with exclusive access to select articles in the from the journal, as well as interviews with authors from our papers in ‘Peek behind the Paper’ style interviews. A notable highlight is an interview with Lauren Endres (State University of New York Polytechnic Institute; NY, USA) where readers can learn more about the emerging roles of tRNA modifications in cancer – in both a preventative and therapeutic role. You can also read the full paper here.
Follow with us on social media
The journal also continues to be active across social media, and we are keen for you to engage. Follow us on Twitter at @fsgfmc and on LinkedIn to stay updated with our latest content – including our journal highlights and the latest medicinal chemistry news.
We appreciate the support and engagement that has been provided over the past year and look forward to what is to come in 2020. As always, we are happy for you to submit any unsolicited articles to the journal – whether they are original research, reviews or opinion pieces. If you have a submission that you would like us to consider, you can find details on article preparation or submission online or get in touch.
Finally, we would like to thank everyone for their continued feedback and support - we look forward to working with all of you over the coming year!